Inspira Technologies (NASDAQ: IINN) advances $49.5M orders toward approval
Rhea-AI Filing Summary
Inspira Technologies reported procedural progress on two previously announced binding purchase orders of $22.5 million and $27 million. The company’s distribution partner notified Inspira that these orders have moved to the final governmental budgetary validation and fund allocation stage within the relevant authorities’ procurement processes.
Approximately 91% of the purchase order value has passed commercial and administrative review and is now in the last budgetary authorization step before funds can be released and operations executed, subject to customary governmental approvals. Inspira reiterated that payment and revenue recognition related to these orders are expected during the 2026 fiscal cycle, in line with the governmental budget cycle and deployment milestones, and noted it has completed internal preparations for execution.
Positive
- None.
Negative
- None.
Insights
Large prior orders advance to final government budget approval.
Inspira Technologies highlights procedural progress on two binding purchase orders totaling
The update specifies that about
The impact ultimately depends on completion of governmental budgetary procedures and subsequent deployment. Future company disclosures for the
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2026 (Report No. 3)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On January 21, 2026, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) issued a press release titled “Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
The first five paragraphs and the section titled “Forward-Looking Statements” of the press release attached hereto as Exhibit 99.1, is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. | ||
| 99.1 | Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on January 21, 2026, titled “Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders.” |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Inspira Technologies Oxy B.H.N. Ltd. | |||
| Date: January 21, 2026 | By: | /s/ Dagi Ben-Noon | |
| Name: | Dagi Ben-Noon | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Inspira Advances to Final Governmental Budgetary
Validation Procedures for
Previously Announced Binding Purchase Orders
RA’ANANA, Israel, January 21, 2026 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders.
The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 2025 and August 19, 2025, respectively, have advanced to the final budgetary validation and fund allocation stage within the relevant governmental authorities’ procurement processes.
According to the notification, approximately 91% of the purchase orders have cleared commercial and administrative review stages and are now undergoing final budgetary authorization procedures, which represent the concluding administrative step before fund release and operational execution, subject to completion of customary governmental approval processes.
As previously disclosed in the Company’s December 23, 2025 update, payment and revenue recognition relating to these purchase orders is expected during 2026 fiscal cycle, aligned with the completion of the governmental budgetary cycle and subsequent deployment milestones.
The Company has completed its internal preparations for execution and will provide further updates as material milestones are reached.
Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: “We continue to work closely with our distribution partners and governmental stakeholders on the execution of these purchase orders. Advancement to the final budgetary stage is a procedural step in complex international procurement processes. We remain focused on converting our contracted backlog into delivered systems and recognized revenue.”
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the status, progression, and potential execution of its previously announced binding purchase orders, the completion of remaining governmental budgetary validation, authorization, and fund allocation procedures, the timing thereof, fund release, delivery, deployment, payment and revenue recognition related to these purchase orders, the Company’s operational readiness to execute and fulfill the agreements, and the conversion of its contracted backlog into delivered systems and recognized revenue. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ
What did Inspira Technologies (IINN) announce in this 6-K filing?
Inspira Technologies reported that two previously announced binding purchase orders have advanced to the final governmental budgetary validation and fund allocation stage. These orders have largely cleared commercial and administrative review and are now in the last budgetary authorization step before funds can be released and operations executed, subject to customary approvals.
What is the value of the binding purchase orders mentioned by Inspira Technologies (IINN)?
The company referenced two binding purchase orders with values of $22.5 million and $27 million. These contracts were originally announced on July 2, 2025 and August 19, 2025, and remain subject to completion of governmental budgetary validation and authorization procedures.
How far along are Inspira Technologies government-related procurement processes?
According to the update, approximately 91% of the purchase order value has passed commercial and administrative review stages. The remaining step is final budgetary authorization and fund allocation by the relevant governmental authorities, which is described as the concluding administrative stage before funds are released and operational execution begins, subject to customary governmental approvals.
When does Inspira Technologies expect to recognize revenue from these purchase orders?
The company states that payment and revenue recognition relating to these binding purchase orders is expected during the 2026 fiscal cycle. This timing is described as aligned with the completion of the governmental budgetary cycle and subsequent deployment milestones associated with the contracts.
How is Inspira Technologies preparing to fulfill these binding purchase orders?
Inspira Technologies indicates it has completed its internal preparations for execution of the purchase orders. The company notes it will provide further updates as material milestones are reached, while continuing to collaborate with its distribution partners and governmental stakeholders on execution.
What products and technologies does Inspira Technologies focus on?
Inspira Technologies is described as a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and serves as a base for the INSPIRA ART500 system under development. The company is also advancing HYLA, a blood sensor platform for continuous, non-invasive monitoring.
